Mesothelioma and radical multimodality therapy: who benefits?

  title={Mesothelioma and radical multimodality therapy: who benefits?},
  author={David J. Sugarbaker and Michael Thomas Jaklitsch and Michael J. Liptay},
  volume={107 6 Suppl},
The incidence of malignant pleural mesothelioma is increasing. Untreated, patients with this disease experience a rapid and horrendous clinical decline. Surgery plays a role in the diagnosis, staging, and treatment of this malignancy. Surgery, chemotherapy, and radiotherapy alone have been unable to achieve major improvements in survival for most patients. More recent phase II trials suggest that surgery, at one time a purely palliative approach, may have a potentially curative role when used… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 12 extracted citations


Publications referenced by this paper.
Showing 1-10 of 28 references

Late effects of cancer treatment : radiation and drug toxicity

  • CA Perez, LW Brady
  • Chest Surg Clin Am
  • 1994

Randomized phase IL trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B

  • DJ Sugarbaker, SJ Mentzer, G Strauss
  • J Clin Oncol
  • 1993

The role of extrapleural pneumonectomy in malignant pleural mesothelioma : a Lung Cancer Study Group trial

  • F Nagasaki
  • J Thorac Cardiovasc Surg
  • 1991

Methods of cancer surveillance

  • RW Clapp
  • Dis Abstr Int
  • 1989

Similar Papers

Loading similar papers…